Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 17α-ethynyl-androst-5-ene-3,7,17-triol

            Therapeutic Area: Endocrinology Product Name: NE3107

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2021

            Details:

            NE3107, a new drug candidate in development for Alzheimer’s and Parkinson’s Diseases and other conditions, is an ERK inhibitor that selectively inhibits neuroinflammation and insulin resistance.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): miRNA Based Therapy

            Therapeutic Area: Endocrinology Product Name: RSVI-301

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Nexturn Bio

            Deal Size: $5.5 million Upfront Cash: Undisclosed

            Deal Type: Acquisition May 30, 2021

            Details:

            RosVivo's new miRNA drug RSVI-301 significantly reduces injection frequency, showed a prolonged effect, and alleviated side effects such as GI dysmotility in animal studies. It is expected that RSVI-301 will become a first-in-class diabetic drug.